1,4-Oxathiocane | 25042-07-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-Oxathiocane
• CAS: 25042-07-3
• 化学式: C₆H₁₂OS
• 分子量: 132.23
• InChiKey: QNNUQDYYZAMNPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20180289677A1

  公开（公告）日：2018-10-11

  Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  揭示了DCN1的小分子共价抑制剂和含有这些抑制剂的组合物。还揭示了在治疗疾病和状况中使用DCN1共价抑制剂的方法，其中DCN1的抑制提供益处，如氧化应激相关的疾病和状况、神经退行性疾病和状况、代谢紊乱以及肌肉神经退化。
• 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators
  申请人：——

  公开号：US20040014743A1

  公开（公告）日：2004-01-22

  The present invention is directed to novel 2-(quinolonyl)-fused heterocyclyl derivatives of the general formula (I) 1 wherein R 1 , R 2 , R 3 , R 3a , R 4 , R 5 , R 6 and R 7 are as herein defined, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及一种新颖的一般式（I）的2-(喹啉基)-融合杂环基衍生物，其中R1、R2、R3、R3a、R4、R5、R6和R7如所定义，包含它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的用途。
• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
• 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1501835A2

  公开（公告）日：2005-02-02